|Table of Contents|

Discovery of SARS-CoV-2 Inhibitor from Traditional ChineseMedicine Based on Virtual Screening(PDF)

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2021年02期
Page:
141-148
Research Field:
·药学·
Publishing date:

Info

Title:
Discovery of SARS-CoV-2 Inhibitor from Traditional ChineseMedicine Based on Virtual Screening
Author(s):
Wen Zeyu1; Song Yu1; Gong Meina1; Liu Yitong2; Cao Hongyu1; Shi Liying1
(1.School of Life Sciences and Biotechnology,Dalian University,Dalian 116622,China)(2.Institute of Medical Biotechnology,Chinese Academy of Medical Sciences,Beijing 100050,China)
Keywords:
SARS-CoV-2; molecular docking; virtual screening; structure activity relationship
PACS:
R284.1
DOI:
10.3969/j.issn.1001-4616.2021.02.020
Abstract:
The main protease(Mpro)of the SARS-CoV-2 plays an important role in the self-replication process,and drugs targeting the main protease can treat SARS-CoV-2 infections. Therefore,it was conducted a virtual screening on the traditional Chinese medicine database:TCMD,and the compounds obtained by the screening meet the Lipinski rule and the Veber rule,and the compounds obtained by the TOPKAT prediction. The compounds obtained by the screening have good pharmaceutical properties. Studying the interaction mode under molecular docking and verifying the stability of the complex system through free binding energy. The results showed that the compound 1(ZINC33830770,triterpenes from Ganoderma lucidum)and the compound 4(ZINC13358899,isobutylamides of unsaturated fatty acids from chrysanthemum morifolium)were confirmed to be similar to the positive control drug Talampicillin,shows strong affinity and stability in the active pocket of the main protease. Therefore,compound 1 and compound 4 can play a potential preventive effect on COVID-19 by inhibiting the Mpro.

References:

[1] JEE Y. WHO International Health Regulations Emergency Committee for the COVID-19 outbreak[J]. Epidemiol health,2020,42:e2020013.
[2]HSIEH C C,LIN C H,WANG W Y C,et al. The outcome and implications of public precautionary measures in taiwan-declining respiratory disease cases in the COVID-19 pandemic[J]. International journal of environmental research and public health,2020,17(13):4877.
[3]LU R,ZHAO X,LI J,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J]. Lancet,2020,395(10224):565-574.
[4]DAI Y,CHEN S R,CHAI L,et al. Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide[J]. Critical revriews in food science and nutrition,2019,59(sup1):S17-S29.
[5]ZHOU P,YANG X L,WANG X G,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature,2020,579(7798):270-273.
[6]WU C,LIU Y,YANG Y,et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods[J]. Acta pharmaceutica sinica B,2020,10(5):766-788.
[7]LI W,XU C,HAO C,et al. Inhibition of herpes simplex virus by myricetin through targeting viral gD protein and cellular EGFR/PI3K/Akt pathway[J]. Antiviral research,2020,177:104714.
[8]ANAND K,PALM G J,MESTERS J R,et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain[J]. The embo journal,2002,21(13):3213-3224.
[9]ZHOU J,FANG L,YANG Z,et al. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach[J]. The faseb journal,2019,33(12):14575-14587.
[10]ANAND K,ZIEBUHR J,WADHWANI P,et al. Coronavirus main proteinase(3CLpro)structure:basis for design of anti-SARS drugs[J]. Science,2003,300(5626):1763-1767.
[11]PILLAIYAR T,MANICKAM M,NAMASIVAYAM V,et al. An overview of severe acute respiratory syndrome-coronavirus(SARS-CoV)3CL protease inhibitors:peptidomimetics and small molecule chemotherapy[J]. Journal of medicinal chemistry,2016,59(14):6595-6628.
[12]DONG L,HU S,GAO J. Discovering drugs to treat coronavirus disease 2019(COVID-19)[J]. Drug discoveries & therapeutics,2020,14(1):58-60.
[13]CAO B,WANG Y,WEN D,et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19[J]. New England journal of medicine,2020,382(19):1787-1799.
[14]陈军,凌云,席秀红. 洛匹那韦利托那韦和阿比多尔用于治疗新型冠状病毒肺炎的有效性研究[J]. 中华传染病杂志,2020(2):86-89.
[15]VINCENT M J,BERGERON E,BENJANNET S,et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J]. Virology journal,2005,2:69.
[16]于明坤,柴倩云,梁昌昊,等. 新型冠状病毒肺炎中医预防及诊疗方案汇总分析[J]. 中医杂志,2020,61(5):383-387.
[17]姜皓,赵士博,张艺馨,等. 新冠肺炎中医药诊治预防及地区治疗特色研究进展[J]. 中国医院药学杂志,2020,40(17):1896-1901.
[18]ELMEZAYEN A D,AL-OBAIDI A, �瘙 塁 AHIN A T,et al. Drug repurposing for coronavirus(COVID-19):in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes[J]. Journal of biomolecular structure and dynamics,2021,29(8):2980-2992.
[19]JIN Z,DU X,XU Y,et al. Structure of M(pro)from SARS-CoV-2 and discovery of its inhibitors[J]. Nature,2020,582(7811):289-293.
[20]LIPINSKI C A. Chris Lipinski discusses life and chemistry after the Rule of Five[J]. Drug discovery today,2003,8(1):12-16.
[21]林志彬,罗俊. 灵芝三萜类化合物药理作用研究进展[J]. 药学学报,2002,34(7):574-578.
[22]TSAO R,ATTYGALLE A B,SCHROEDER F C,et al. Isobutylamides of unsaturated fatty acids from Chrysanthemum morifolium associated with host-plant resistance against the western flower thrips[J]. Journal of natural products,2003,66(9):1229-1231.
[23]YUAN H,JIANG S,LIU Y,et al. The flower head of Chrysanthemum morifolium Ramat.(Juhua):A paradigm of flowers serving as Chinese dietary herbal medicine[J]. Journal of ethnopharmacology,2020,261:113043.

Memo

Memo:
-
Last Update: 2021-06-30